Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:50 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 2,412 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Laboratory testing Clear all
Active, not recruiting No phase listed Observational

The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study

NCT02520713
View directory record Official record
Conditions
Pediatric Solid Tumor
Interventions
Genetic testing and GAIN report
Genetic
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 30 Years
Enrollment
825 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
12
States / cities
San Francisco, California • Aurora, Colorado • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Rutgers Pilot for PREDICT- Patient LAB Test

NCT05607043
View directory record Official record
Conditions
SARS-CoV2 Infection
Interventions
Testing for SARS CoV2 RNA
Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 22, 2023 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 3 Interventional Results available

Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics

NCT02905825
View directory record Official record
Conditions
Helicobacter Pylori Infection
Interventions
BreathID® Hp System, BreathID® Hp Lab System, Stool Test
Device · Drug · Diagnostic Test
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
3 Years to 18 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
5
States / cities
Shreveport, Louisiana • Flowood, Mississippi • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Flourish: Exploring the Early Infant Gut Microbiome

NCT07333482
View directory record Official record
Conditions
Microbiota, Gut Microbiome, Eczema, Microbiome
Interventions
Tailored Recommendations, Consult Call, Educational Email Series
Dietary Supplement · Behavioral
Lead sponsor
Seeding Inc
Industry
Eligibility
0 Months to 3 Months
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Active, not recruiting No phase listed Observational

Biomarkers of Immune-Related Toxicity

NCT03409016
View directory record Official record
Conditions
Cancer, Metastatic Cancer
Interventions
Blood Testing
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 1 Interventional

Statin Therapy to Improve Medication Adherence

NCT01894217
View directory record Official record
Conditions
Hypercholesterolemia, HMG COA Reductase Inhibitor Adverse Reaction
Interventions
Genetic testing and reporting for SLCO1B1*5 allele
Genetic
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparing the Effects of Exercise on the Structure and Function of Fat Tissue

NCT05328570
View directory record Official record
Conditions
Adiposity
Interventions
Oral Glucose Tolerance Test
Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 40 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Lipoprotein Kinetics in T1D

NCT05179954
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Metabolic testing
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed No phase listed Observational

Relationship Between Vitamin D Biomarkers and Survival in Blood Samples From Patients With Advanced Pancreatic Cancer

NCT01327794
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
polymorphism analysis, immunologic technique, laboratory biomarker analysis, medical chart review
Genetic · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Glens Falls, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Phase 1 Interventional

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions
Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional

Comprehensive Genetic Assessment, Risk and Education in a Mammography Pilot

NCT04002986
View directory record Official record
Conditions
Women Age 35+ Qualifies if >15% Lifetime Risk of Breast Cancer as Defined by IBIS Version 8
Interventions
Genetic Testing
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
35 Years and older · Female only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Not applicable Interventional

Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules

NCT05229341
View directory record Official record
Conditions
Thyroid Gland Carcinoma
Interventions
Diagnostic Procedure, Electronic Health Record Review, Needle Biopsy
Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
1,450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Results available

FOB in HSCT and Leukemia Patients With Acute Respiratory Symptoms and Pulmonary Infiltrates

NCT01328873
View directory record Official record
Conditions
Pulmonary Infiltrate New
Interventions
Microbiological analysis
Other
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Phase 1 Interventional

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641
View directory record Official record
Conditions
Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Resectable Glioblastoma
Interventions
Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801, Fludeoxyglucose F-18, Magnetic Resonance Imaging, Positron Emission Tomography, Surgical Procedure
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Addressing Disparities in Colorectal Cancer Screening in Black and Underserved Phoenix Communities

NCT05447923
View directory record Official record
Conditions
Colorectal Carcinoma
Interventions
Educational Intervention, Fecal Immunochemical Test, Patient Navigation, Questionnaire Administration
Other · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
45 Years and older
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2030
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Phase 1 Interventional

Testing for Safety and Colorectal Cancer Preventive Effects of ONC201

NCT05630794
View directory record Official record
Conditions
Colorectal Adenomatous Polyp, Colorectal Carcinoma, Familial Adenomatous Polyposis, Multiple Adenomatous Polyps
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Dordaviprone Hydrochloride, Endoscopic Procedure, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Cleveland, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants

NCT02691156
View directory record Official record
Conditions
Bilirubin-induced Neurologic Dysfunction, Hyperbilirubinemia, Kernicterus, Infant, Premature, Infant, Low Birth Weight
Interventions
Bilirubin Binding Capacity, End-tidal Carbon Monoxide, Carboxyhemoglobin
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
24 Weeks to 34 Weeks
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2021 · Synced Oct 21, 2026, 9:50 PM EDT
Terminated No phase listed Interventional Results available

Intended Use Study of the BD SurePath Plus™ Pap

NCT01234480
View directory record Official record
Conditions
Uterine Cervical Neoplasms, Uterine Cervical Cancer, Neoplasms, Squamous Cell, Neoplasms, Glandular and Epithelial, Neoplasms by Histologic Type, Neoplasms, Papilloma
Interventions
BD SurePath Plus Pap test, BD SurePath Pap test, colposcopy with biopsy/ECC, HPV DNA test
Device · Procedure
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
5,859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 1 Interventional

Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

NCT00000756
View directory record Official record
Conditions
HIV Infections
Interventions
Lymphocytes, Activated
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Phase 2 Interventional

Laboratory Test in Predicting Response to Erlotinib in Patients With Relapsed Metastatic or Unresectable Non-Small Cell Lung Cancer That Did Not Respond to Previous Treatment

NCT00673569
View directory record Official record
Conditions
Lung Cancer
Interventions
erlotinib hydrochloride, gene expression analysis, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, needle biopsy
Drug · Genetic · Other + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 9, 2010 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Phase 2 Interventional

Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors

NCT04665739
View directory record Official record
Conditions
Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor
Interventions
Biospecimen Collection, Computed Tomography, Everolimus, Fludeoxyglucose F-18, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Positron Emission Tomography, Single Photon Emission Computed Tomography, Survey Administration
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
29
States / cities
Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 9:50 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Capturing Autobiographical Memory Formation in Real World Spaces Using Multimodal Recordings

NCT06883981
View directory record Official record
Conditions
Epilepsy, Autobiographical Memory
Interventions
Free and Cued Recall Memory. Temporal Sequence and Spatial Memory
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Oct 21, 2026, 9:50 PM EDT
Terminated Phase 2 Interventional Results available

Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

NCT02839681
View directory record Official record
Conditions
Lung Neoplasms
Interventions
Anetumab Ravtansine, Blood test
Drug · Device
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 21, 2026, 9:50 PM EDT
Completed Not applicable Interventional Results available

Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)

NCT00933400
View directory record Official record
Conditions
Chest Pain, Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease
Interventions
CT Coronary Angiography (CTCA), Traditional Strategy
Diagnostic Test · Procedure
Lead sponsor
American College of Radiology
Other
Eligibility
30 Years and older
Enrollment
1,392 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Winston-Salem, North Carolina • Hershey, Pennsylvania • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 21, 2026, 9:50 PM EDT